CD19 and acute lymphoblastic leukemia: In an analysis of efficacy of tisagenlecleucel in patients with R/R B-ALL from two pediatric trials (ELIANA and ENSIGN), the authors showed that patients who experienced CD19-positive relapses had more rapid loss of tisagenlecleucel persistence in comparison with those who achieved durable remissions [56].